Literature DB >> 8348753

Antimitochondrial autoantibodies in anti-glomerular basement membrane disease.

J B Marriott1, D B Oliveira.   

Abstract

Anti-glomerular basement membrane (GBM) disease is characterized by the production of an autoantibody with very restricted specificity, with no evidence of polyclonal B cell activation. It was therefore surprising to find that in a solid-phase ELISA a proportion of anti-GBM sera showed significant binding to pyruvate dehydrogenase (PDH), a reactivity usually associated with the antimitochondrial autoantibodies (AMA) found in primary biliary cirrhosis (PBC). The specificity of this reactivity was confirmed by inhibition and competition experiments. The AMA found in anti-GBM sera were of much lower affinity than those found in PBC sera, and recognized a more restricted set of species (mainly the 55-kD and occasionally the 74-kD component of PDH). However, it was possible to block the binding in a Western blot of an anti-GBM serum to both the 55-kD and 74-kD species with F(ab')2 fragments prepared from a PBC serum. Although AMA have been found in diseases other than PBC, such diseases have usually been characterized by polyclonal B cell activation. The stimulus to the production of AMA in anti-GBM disease, and their significance in pathogenesis (if any), are unknown.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8348753      PMCID: PMC1554833          DOI: 10.1111/j.1365-2249.1993.tb07976.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  25 in total

1.  Anti-mitochondrial antibody IgG subclass distribution and affinity in primary biliary cirrhosis.

Authors:  L Zhang; A P Weetman; D R Jayne; I Turner; S J Yeaman; M F Bassendine; D B Oliveira
Journal:  Clin Exp Immunol       Date:  1992-04       Impact factor: 4.330

2.  Determination of the functional affinity of IgG1 and IgG4 antibodies to tetanus toxoid by isotype-specific solid-phase assays.

Authors:  M E Devey; K Bleasdale; S Lee; S Rath
Journal:  J Immunol Methods       Date:  1988-01-21       Impact factor: 2.303

3.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

Review 4.  Primary biliary cirrhosis.

Authors:  M M Kaplan
Journal:  N Engl J Med       Date:  1987-02-26       Impact factor: 91.245

5.  Prospective study of radioimmunoassay for antibodies against neutrophil cytoplasm in diagnosis of systemic vasculitis.

Authors:  C O Savage; C G Winearls; S Jones; P D Marshall; C M Lockwood
Journal:  Lancet       Date:  1987-06-20       Impact factor: 79.321

6.  Clinical application of a radio-immunoassay for auto-antibodies to glomerular basement membrane.

Authors:  C Bowman; C M Lockwood
Journal:  J Clin Lab Immunol       Date:  1985-08

7.  A follow-up study of 68 patients with anti-mitochondrial antibodies (AMA).

Authors:  R Jorde; O P Rekvig; L Bostad
Journal:  Acta Med Scand       Date:  1986

8.  A single autoantigen in Goodpasture's syndrome identified by a monoclonal antibody to human glomerular basement membrane.

Authors:  C D Pusey; A Dash; M J Kershaw; A Morgan; A Reilly; A J Rees; C M Lockwood
Journal:  Lab Invest       Date:  1987-01       Impact factor: 5.662

9.  High prevalence of anti-mitochondrial antibodies among patients with some well-defined connective tissue diseases.

Authors:  S Mouritsen; E Demant; H Permin; A Wiik
Journal:  Clin Exp Immunol       Date:  1986-10       Impact factor: 4.330

10.  The in vitro production of antibodies to mitochondrial antigens by peripheral blood mononuclear cells from patients with primary biliary cirrhosis.

Authors:  M I Avigan; G Adamson; J H Hoofnagle; E A Jones
Journal:  Hepatology       Date:  1986 Sep-Oct       Impact factor: 17.425

View more
  1 in total

1.  Serial functional affinity of autoantibodies in anti-glomerular basement membrane disease.

Authors:  J B Marriott; D B Oliveira
Journal:  Clin Exp Immunol       Date:  1994-03       Impact factor: 4.330

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.